Runben Biotechnology (SH:603193) Guoyuan Securities·2025-10-22 08:13Investment Rating - The report maintains a "Buy" rating for Runben Co., Ltd. (603193) [4] Core Insights - The company's revenue for Q1-Q3 2025 reached 1.238 billion yuan, a year-on-year increase of 19.28%, while net profit attributable to the parent company was 266 million yuan, up 1.98% year-on-year [2] - The mosquito repellent category saw significant growth due to the impact of Chikungunya fever, with Q3 revenue for this category increasing by 48.54% year-on-year [3] - The company is focusing on a "big brand, small category" integrated strategy, driving growth through mosquito repellent and personal care segments [4] Financial Performance Summary - For Q1-Q3 2025, the gross margin was 58.27%, a slight decrease of 0.06 percentage points year-on-year, while the net profit margin was 21.5%, down 3.65 percentage points year-on-year [2] - The sales expense ratio increased to 29.93%, up 2.66 percentage points year-on-year, contributing to pressure on profitability [2] - The company expects net profit attributable to the parent company to reach 314 million yuan in 2025, with EPS projected at 0.78 yuan per share [4] Revenue Breakdown - The mosquito repellent category generated 508 million yuan in revenue for Q1-Q3 2025, a year-on-year increase of 20.88%, while the baby care category saw revenue of 551 million yuan, up 24.64% year-on-year [3] - In Q3 alone, the mosquito repellent category achieved revenue of 132 million yuan, with an average price increase of 12.04% year-on-year [3] - The essential oil category, however, experienced a decline in revenue, totaling 130 million yuan, down 12.34% year-on-year [3]